Biotechnology Companies By Cash Per Share
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Cash Per Share
| Cash Per Share | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | GLPG | Galapagos NV ADR | (0.07) | 2.20 | (0.15) | ||
| 2 | REGN | Regeneron Pharmaceuticals | (0.37) | 1.82 | (0.67) | ||
| 3 | BGNE | BeiGene | (0.07) | 2.76 | (0.18) | ||
| 4 | UTHR | United Therapeutics | 0.02 | 1.86 | 0.04 | ||
| 5 | IMAB | I Mab | (0.02) | 5.44 | (0.11) | ||
| 6 | ARGX | argenx NV ADR | 0.14 | 1.97 | 0.27 | ||
| 7 | BNTX | BioNTech SE | 0.01 | 2.72 | 0.03 | ||
| 8 | VRTX | Vertex Pharmaceuticals | (0.03) | 1.76 | (0.05) | ||
| 9 | BIIB | Biogen Inc | (0.32) | 1.38 | (0.43) | ||
| 10 | GMAB | Genmab AS | (0.24) | 1.56 | (0.37) | ||
| 11 | CRSP | Crispr Therapeutics AG | (0.06) | 3.38 | (0.20) | ||
| 12 | THRD | Third Harmonic Bio | (0.09) | 4.79 | (0.41) | ||
| 13 | SAGE | Sage Therapeutic | (0.11) | 4.73 | (0.51) | ||
| 14 | SRPT | Sarepta Therapeutics | (0.02) | 2.79 | (0.05) | ||
| 15 | CNTB | Connect Biopharma Holdings | (0.04) | 5.13 | (0.23) | ||
| 16 | ITOS | Iteos Therapeutics | (0.23) | 2.86 | (0.65) | ||
| 17 | MRNA | Moderna | (0.23) | 3.43 | (0.79) | ||
| 18 | AMGN | Amgen Inc | (0.21) | 1.68 | (0.35) | ||
| 19 | ALNY | Alnylam Pharmaceuticals | (0.09) | 2.18 | (0.20) | ||
| 20 | LSTA | Lisata Therapeutics | (0.10) | 3.00 | (0.29) |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it. Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.